Published • loading... • Updated
FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata
Summary by The Paintsville Herald
11 Articles
11 Articles
keenesentinel.com+7 Reposted by 7 other sources
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA)
Eli Lilly received extended approval from the U.S. Food and Drug Regulatory Agency (FDA) for Olumiant, a medicine intended for paediatric patients 12 years of age or older suffering from severe alopecia. Exclusive material for subscribers. To have full access, access the link of the material and register.
·Rio de Janeiro, Brazil
Read Full Article
Coverage Details
Total News Sources11
Leaning Left1Leaning Right4Center4Last UpdatedBias Distribution45% Center, 44% Right
Bias Distribution
- 45% of the sources are Center, 44% of the sources lean Right
45% Center
11%
C 45%
R 44%
Factuality
To view factuality data please Upgrade to Premium
